Unlock instant, AI-driven research and patent intelligence for your innovation.

Compounds and methods for inhibiting phosphate transport

By inhibiting small intestinal phosphate uptake using non-NHE3-binding compounds such as guanylyl cyclase C receptor agonists and pH regulators in the gastrointestinal tract, the hypercalcemia problem of existing phosphate binders to treat hyperphosphatemia is solved. symptoms and gastrointestinal discomfort, achieving safe and efficient regulation of serum phosphorus levels and alleviation of renal failure.

Active Publication Date: 2021-11-30
ARDELYX INC
View PDF246 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such mechanisms have been poorly explored in the field of phosphate-lowering therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0621] Increased intracellular pH results in decreased phosphate uptake in cells

[0622] Experiments were performed to test the relationship between changes in intracellular pH and the uptake of phosphate ions (Pi) in human embryonic kidney cells (HEK-293 cells).

[0623] HEK-293 cells were seeded into 96-well plates at 25,000 cells / well and cultured overnight. Cells were then transfected with rat or human NaP2b cDNA, or mock-transfected (no DNA) using Lipofectamine 2000 (Invitrogen). Cells were brought near confluency during the second overnight incubation.

[0624] The intracellular pH was lowered from about 7.4 to about 6.8 using an ammonium pulse program. Aspirate the culture medium from the well and wash with NaCl-HEPES buffer (100mM NaCl, 50mM HEPES, 10mM glucose, 5mM KCl, 2mM CaCl 2 , 1mM MgCl 2 , pH 7.4) washed the cells twice, and then mixed with NH containing 5 μM BCECF-AM at room temperature 4 Cl-HEPES buffer (20mM NH 4 Cl, 80mM NaCl, 50mM HEPES, 5mM KCl, 2mM...

Embodiment 2

[0629] Guanylate cyclase C (GC-C) receptor agonists reduce phosphate uptake

[0630] Experiments were performed to determine whether guanylate cyclase C (GC-C) receptor agonists could reduce the 33 Phosphate absorption / uptake in the small intestine measured by P uptake. use 33 P and linaclotide were administered to rats simultaneously as follows:

[0631] 1. Vehicle (N=5 / group)

[0632] 2. Linaclotide at 0.1 mg / kg (N=6 / group)

[0633] 3. Linaclotide at 0.3mg / kg (N=4 / group)

[0634] exist 33 Blood was collected 5, 15, 30, 45 and 60 min after P administration and plasma scintillation counts were performed. The results are shown in Figures 1A-1B middle. Figure 1A The results of a two-way ANOVA using repeated measures followed by Dunnett's multiple comparison test are shown, and Figure 1B Results of one-way ANOVA followed by Dunnett's multiple comparison test are shown. These results showed that both doses of linaclotide decreased phosphate absorption from the gastroi...

Embodiment 3

[0636] I1 receptor agonists and adenylyl cyclase agonists reduce phosphate uptake

[0637] Conduct experiments to determine whether other classes of drugs can reduce 33 Phosphate absorption / uptake in the small intestine measured by P uptake. use 33 P and imidazoline subtype 1 (I 1 ) receptor agonist (moxonidine) or adenylyl cyclase agonist (water-soluble forskolin analogue NKH477) were administered to rats simultaneously as follows:

[0638] 1. Medium

[0639] 2. Moxonidine at 2mg / kg

[0640] 3. Moxonidine at 6mg / kg

[0641] 4. NKH477 at 1mg / kg

[0642] 5. NKH477 at 3mg / kg

[0643] exist 33 Blood was collected 5, 15, 30, 45 and 60 min after P administration and plasma scintillation counts were performed. The results are shown in Figure 2A-2B middle. Figure 2A Shown are the results of a two-way ANOVA using repeated measures, followed by Dunnett's multiple comparison test, and Figure 2B Results of one-way ANOVA followed by Dunnett's multiple comparison test are sh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This provides non-NHE3 binders with activity as phosphate transport / uptake inhibitors in the gastrointestinal tract, including the small intestine, methods for their use as therapeutic or preventative agents, and related methods for drug discovery.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Application No. 61 / 864,215, filed August 9, 2013, and U.S. Application No. 61 / 936,715, filed February 6, 2014, each of which is incorporated by reference in its entirety way incorporated. [0003] Statement Regarding Sequence Listing [0004] The Sequence Listing related to this application is provided in text format instead of hard copy and is hereby incorporated by reference into this specification. The name of the text file containing the sequence listing is ARDE_017_01WO_ST25.txt. This text file is 193KB, was created on August 8, 2014, and was submitted electronically via EFS-Web. technical field [0005] The present invention relates to non-NHE3 binders having activity as phosphate transport inhibitors in the gastrointestinal tract including the small intestine, methods of use as therapeutic or prophylactic agents, and related methods of drug dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/10A61K31/197A61K31/437A61K31/4427A61P13/12
CPCA61K31/00A61K38/16A61K38/10A61P1/00A61P13/02A61P13/12A61P3/12A61P5/20A61P7/00A61K2300/00G01N33/5044G01N33/84A61K31/4045A61K31/195A61K31/382G01N33/5038A61K31/421A61K31/27A61K31/506A61K31/353A61K31/4418A61P9/00A61K31/4439A61K45/06A61K31/352A61K31/4525A61K31/475A61K31/7072A61P43/00A61K33/26
Owner ARDELYX INC